• 1
    Brook RH. Practice guidelines: to be or not to be. Lancet. 1996;348:10056.
  • 2
    Cluzeau F, Littlejohns P, Grimshaw JM. Appraising clinical guidelines: towards a “which” guide for purchasers. Qual Health Care. 1994;3(3):1212.
  • 3
    Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med. 1997;127(3):2106.
  • 4
    Eccles M, Clapp Z, Grimshaw J, et al. Developing valid guidelines: methodological and procedural issues from the North of England Evidence Based Guideline Development Project. Qual Health Care. 1996;5(3):4450.
  • 5
    Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA. 1997;278(3):168792.
  • 6
    Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(3):19005.
  • 7
    Grilli R, Magrini N, Penna A, Mura G, Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000;355(3):1036.
  • 8
    Lohr KN, Eleazer K, Mauskopf J. Health policy issues and applications for evidence-based medicine and clinical practice guidelines. Health Policy. 1998;46(3):119.
  • 9
    Eddy DM. Clinical decision making: from theory to practice. Benefit language: criteria that will improve quality while reducing costs. JAMA. 1996;275(3):6507.
  • 10
    Singer PA. Resource allocation: beyond evidence-based medicine and cost-effectiveness analysis. ACP J Club. 1997;127(3):A168.
  • 11
    Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(3):11727.
  • 12
    Cook D, Giacomini M. The trials and tribulations of clinical practice guidelines. JAMA. 1999;281(3):19501.
  • 13
    Hayward RS, Wilson MC, Tunis SR, Bass EB, Guyatt G. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group. JAMA. 1995;274(3):5704.
  • 14
    Wilson MC, Hayward RS, Tunis SR, Bass EB, Guyatt G. Users' guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. JAMA. 1995;274(3):16302.
  • 15
    Institute of Medicine. Clinical Practice Guidelines: Directions of a New Program. Washington DC: National Academy Press; 1990.
  • 16
    Drummond MF, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1987.
  • 17
    Torrance GW, Blaker D, Detsky A, et al. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics. 1996;9(3):53559.
  • 18
    Sanchez LA. Evaluating the quality of published pharmacoeconomic evaluations. Hosp Pharm. 1995;30(3):1468, 1522.
  • 19
    Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics. 1995;8(3):16974.
  • 20
    Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann Pharmacother. 1993;27(3):112633.
  • 21
    The Heart and Stroke Foundation of Canada, the Canadian Cardiovascular Society and the Canadian Association of Emergency Physicians for the Emergency Cardiac Care Coalition. Recommendations for ensuring early thrombolytic therapy for acute myocardial infarction. CMAJ. 1996;154(3):4837.
  • 22
    The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction pre-hospital and in-hospital management. Eur Heart J. 1996;17(3):4363.
  • 23
    American College of Physicians. Guidelines for risk stratification after myocardial infarction. Ann Intern Med. 1997;126(3):55660.
  • 24
    Ades PA, Pashkow FJ, Nestor JR. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. J Cardiopulm Rehabil. 1997;17(3):22231.
  • 25
    Castillo PA, Palmer CS, Halpern MT, Hatziandreu EJ, Gersh BJ. Cost-effectiveness of thrombolytic therapy for acute myocardial infarction. Ann Pharmacother. 1997;31(3):596603.
  • 26
    Davey PJ, Schulz M, Gliksman M, Dobson M, Aristides M, Stephens NG. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial). Cambridge Heart Antioxidant Study. Am J Cardiol. 1998;82(3):4147.
  • 27
    De Boer MJ, Van Hout BA, Liem AL, Suryapranata H, Hoorntje JC, Zijlstra F. A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. Am J Cardiol. 1995;76(3):8303.
  • 28
    Deedwania PC, Amsterdam EA, Vagelos RH. Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management. Arch Intern Med. 1997;157(3):27380.
  • 29
    Gaspoz JM, Lee TH, Weinstein MC, et al. Cost-effectiveness of a new short-stay unit to “rule out” acute myocardial infarction in low risk patients. J Am Coll Cardiol. 1994;24(3):124959.
  • 30
    Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med. 1993;328:68591.
  • 31
    Goel V, Naylor CD. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Can J Cardiol. 1992;8(3):318.
  • 32
    Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998;31(3):96772.
  • 33
    Herve C, Castiel D, Gaillard M, Boisvert R, Leroux V. Cost-benefit analysis of thrombolytic therapy. Eur Heart J. 1990;11(3):100610.
  • 34
    Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10(3):32130.
  • 35
    Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 1992;327(3):713.
  • 36
    Krumholz HM, Cohen BJ, Tsevat J, Pasternak RC, Weinstein MC. Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993;22(3):1697702.
  • 37
    Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation. 1996;94(3):95765.
  • 38
    Levin LA, Jonsson B. Cost-effectiveness of thrombolysis—a randomized study of intravenous rt-PA in suspected myocardial infarction. Eur Heart J. 1992;13(3):28.
  • 39
    Lieu TA, Gurley RJ, Lundstrom RJ, et al. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1997;30(3):174150.
  • 40
    Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96(3):108996.
  • 41
    Lorenzoni R, Pagano D, Mazzotta G, et al. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Eur Heart J. 1998;19(3):151824.DOI: 10.1053/euhj.1998.1092
  • 42
    Machecourt J, Dumoulin J, Calop J, et al. Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours. Eur Heart J. 1993;14(3):7583.
  • 43
    Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332(3):141824 [see comments]. [published erratum appears in N Engl J Med 1995 Jul 27;333(4) 267].
  • 44
    Midgette AS, Wong JB, Beshansky JR, Porath A, Fleming C, Pauker SG. Cost-effectiveness of streptokinase for acute myocardial infarction: a combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. Med Decis Making. 1994;14(3):10817.
  • 45
    Oldridge N, Furlong W, Feeny D, et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. Am J Cardiol. 1993;72(3):15461.
  • 46
    Pedretti RF, Migliori GB, Mapelli V, Daniele G, Podrid PJ, Tramarin R. Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction. J Am Coll Cardiol. 1998;31(3):14819.
  • 47
    Radensky PW, Hilton TC, Fulmer H, McLaughlin BA, Stowers SA. Potential cost effectiveness of initial myocardial perfusion imaging for assessment of emergency department patients with chest pain. Am J Cardiol. 1997;79(3):5959.
  • 48
    Reeder GS, Bailey KR, Gersh BJ, Holmes DR Jr, Christianson J, Gibbons RJ. Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups. Mayo Clin Proc. 1994;69(3):512.
  • 49
    Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28(3):1328428.
  • 50
    Ryan TJ, Antman EM, Brooks NH, et al. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999;34(3):890911.
  • 51
    Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur J Heart. 1991;12(3):6949.
  • 52
    Talat A, Hay J, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996;78(3):40914.
  • 53
    Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26(3):9149.
  • 54
    Vale L, Silcock J, Rawles J. An economic evaluation of thrombolysis in a remote rural community. BMJ. 1997;314(3):5702.
  • 55
    Van Bergen PF, Jonker JJ, Van Hout BA, et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA. 1995;273(3):9258.
  • 56
    Zijlstra F, De Boer MJ, Beukema WP, et al. Mortality, reinfarction, left ventricular ejection fraction and costs following reperfusion therapies for acute myocardial infarction. Eur Heart J. 1996;17:3827.
  • 57
    Scottish Intercollegiate Guidelines Network. Hospital In-Patient Management of Acute Asthma Attacks. A National Clinical Guideline Recommended for Use in Scotland. Edinburgh, Scotland: SIGN; 1996:28 Pilot edition.
  • 58
    National Heart, Lung and Blood Institute. New NHLBI guidelines for the diagnosis and management of asthma. Lippincott Health Promot Lett. 1997;2(3):1, 89.
  • 59
    The Institute for Clinical Systems Integration. Diagnosis and management of asthma. Postgrad Med. 1999;105(3):191202207.
  • 60
    Scottish Intercollegiate Guidelines Network. Primary Care Management of Asthma. A National Clinical Guideline. Edinburgh, Scotland: SIGN; 1998:39.
  • 61
    Grampian Asthma Study of Integrated Care (GRASSIC). Integrated care for asthma: a clinical, social, and economic evaluation. BMJ. 1994;308(3):55964.
  • 62
    Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a medicaid population of asthmatic patients. Clin Ther. 1998;20(3):56780.
  • 63
    Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR. Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. CMAJ. 1996;155(3):2537.
  • 64
    Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. J Gen Intern Med. 1991;6(3):4017.
  • 65
    Booth PC, Wells NE, Morrison AK. A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. Pharmacoeconomics. 1996;10(3):2628.
  • 66
    Doan T, Grammer LC, Yarnold PR, Greenberger PA, Patterson R. An intervention program to reduce the hospitalization cost of asthmatic patients requiring intubation. Ann Allergy Asthma Immunol. 1996;76(3):5138.
  • 67
    Greineder DK, Loane KC, Parks P. Outcomes for control patients referred to a pediatric asthma outreach program: an example of the Hawthorne effect. Am J Manag Care. 1998;4(3):196202.
  • 68
    Greineder DK, Loane KC, Parks P. A randomized controlled trial of a pediatric asthma outreach program. J Allergy Clin Immunol. 1999;103:43640.
  • 69
    Holzer SS, Engelhart L, Crown WH, L'Herrou TA, Kennedy ST. Asthma treatment costs using inhaled corticosteroids. Am J Manag Care. 1997;3(3):8917.
  • 70
    Jasper AC, Mohsenifar Z, Kahan S, Goldberg HS, Koerner SK. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest. 1987;91(3):6148.
  • 71
    Kauppinen R, Sintonen H, Tukiainen H. One-year economic evaluation of intensive vs conventional patient education and supervision for self-management of new asthmatic patients. Respir Med. 1998;92(3):3007.
  • 72
    Kelloway JS, Wyatt R. A cost-effectiveness analysis of breath-actuated metered-dose inhalers. Manag Care Interface. 1997;10(3):99107.
  • 73
    Kerridge RK, Glasziou PP, Hillman KM. The use of “quality-adjusted life years” (QALYs) to evaluate treatment in intensive care. Anaesth Intensive Care. 1995;23(3):32231.
  • 74
    Lahdensuo A, Haahtela T, Herrala J, et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ. 1998;316(3):11389.
  • 75
    Levenson T, Grammer LC, Yarnold PR, Patterson R. Cost-effective management of malignant potentially fatal asthma. Allergy Asthma Proc. 1997;18(3):738.
  • 76
    Liljas B, Stadhl E, Pauwels RA. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics. 1997;12:26777.
  • 77
    McDermott MF, Murphy DG, Zalenski RJ, et al. A comparison between emergency diagnostic and treatment unit and inpatient care in the management of acute asthma. Arch Intern Med. 1997;157(3):205562.
  • 78
    Neri M, Migliori GB, Spanevello A, et al. Economic analysis of two structured treatment and teaching programs on asthma. Allergy. 1996;51(3):3139.
  • 79
    O'Connor JF, Singer ME, Richter JE. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. Am J Gastroenterol. 1999;94(3):147280.
    Direct Link:
  • 80
    Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Arch Dis Child. 1995;72(3):3125.
  • 81
    Rutten-van Molken MP, Van Doorslaer EK, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics. 1998;14(3):67184.
  • 82
    Rutten-van Molken MP, Van Doorslaer EK, Jansen MC, Kerstjens HA, Rutten FF. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;151(3):97582.
  • 83
    Rutten-van Molken MP, Van Doorslaer EK, Jansen MC, Van Essen-Zandvliet EE, Rutten FF. Cost effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma. Pharmacoeconomics. 1993;4(3):25770.
  • 84
    Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy: see comments. Pharmacoeconomics. 1993;4(3):34552.
  • 85
    Soondergaard B, Davidsen F, Kirkeby B, Rasmussen M, Hey H. The economics of an intensive education programme for asthmatic patients: a prospective controlled trial. Pharmacoeconomics. 1992;1(3):20712.
  • 86
    Taitel MS, Kotses H, Bernstein IL, Bernstein DI, Creer TL. A self-management program for adult asthma. Part II: Cost-benefit analysis. J Allergy Clin Immunol. 1995;95(3):6726.
  • 87
    Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled beta-agonists v. oral salbutamol in asthma: a randomized double-blind cross-over study. Natl Med J India. 1996;9(3):15962.
  • 88
    Trautner C, Richter B, Berger M. Cost-effectiveness of a structured treatment and teaching programme on asthma. Eur Respir J. 1993;6(3):148591.
  • 89
    Westley CR, Spiecher B, Starr L, et al. Cost effectiveness of an allergy consultation in the management of asthma. Allergy Asthma Proc. 1997;18(3):158.
  • 90
    Williams J, Richards KA. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the Turbohaler inhaler in paediatric patients. UK Study Group. Br J Clin Pract. 1997;51(3):14753.
  • 91
    The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA. 1996;275(3):127080.
  • 92
    Tobacco-use prevention and cessation. For infants, children, adolescents, and adults. Institute for Clinical Systems Integration. Postgrad Med. 1997;101(3):292300302.
  • 93
    Trepka MJ, DiGiuseppi G. Counseling to prevent tobacco use. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams and Wilkins; 1996.
  • 94
    Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278(3):175966.
  • 95
    Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989;261(3):759.
  • 96
    Elder JP, Campbell NR, Mielchen SD, Hovell MF, Litrownik AJ. Implementation and evaluation of a community-sponsored smoking cessation contest. Am J Health Promot. 1991;5(3):2007.
  • 97
    Ershoff DH, Quinn VP, Mullen PD, Lairson DR. Pregnancy and medical cost outcomes of a self-help prenatal smoking cessation program in a HMO. Public Health Rep. 1990;105(3):3407.
  • 98
    Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275(3):124751.
  • 99
    Hueston WJ, Mainous AG III, Farrell JB. A cost-benefit analysis of smoking cessation programs during the first trimester of pregnancy for the prevention of low birthweight. J Fam Pract. 1994;39(3):3537.
  • 100
    Marks JS, Koplan JP, Hogue CJ, Dalmat ME. A cost-benefit/cost-effectiveness analysis of smoking cessation for pregnant women. Am J Prev Med. 1990;6(3):2829.
  • 101
    McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health Syst Pharm. 1996;53(3):4552.
  • 102
    Mudde AN, De Vries H, Strecher VJ. Cost-effectiveness of smoking cessation modalities: comparing apples with oranges? Prev Med. 1996;25(3):70816.
  • 103
    Oster G, Huse DM, Delea TE, Colditz GA. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. JAMA. 1986;256(3):13158.
  • 104
    Parrott S, Godfrey C, Raw M, West R, McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax. 1998;53:1S38S.
  • 105
    Prathiba BV, Tjeder S, Phillips C, Campbell IA. A smoking cessation counsellor: should every hospital have one? J R Soc Health. 1998;118(3):3569.
  • 106
    Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax. 1998;53:1S19S.
  • 107
    Serxner S, Adams VG, Hundahl LS, Lau S, Adessa CJ Jr, Hopkins D. A smoking cessation pilot program. Hawaii Med J. 1993;52(3):26672.
  • 108
    Shipp M, Croughan-Minihane MS, Petitti DB, Washington AE. Estimation of the break-even point for smoking cessation programs in pregnancy. Am J Public Health. 1992;82(3):38390.
  • 109
    Sofian NS, McAfee T, Wilson J, Levan S. Telephone smoking cessation intervention: the free and clear program. HMO Pract. 1995;9(3):1446.
  • 110
    Warner KE, Smith RJ, Smith DG, Fries BE. Health and economic implications of a work-site smoking-cessation program: a simulation analysis. J Occup Environ Med. 1996;38(3):98192.
  • 111
    Wasley MA, McNagny SE, Phillips VL, Ahluwalia JS. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 1997;26(3):26470.
  • 112
    Wetter DW, Fiore MC, Gritz ER, et al. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. Findings and implications for psychologists. Am Psychol. 1998;53(3):65769.
  • 113
    Windsor RA, Lowe JB, Perkins LL, et al. Health education for pregnant smokers: its behavioral impact and cost benefit. Am J Public Health. 1993;83(3):2016.
  • 114
    U.S. Congress, Office of Technology Assessment. Cost-Effectiveness of Colorectal Cancer Screening in Average-Risk Adults. OTA-BP-H-146. Washington DC: U. S. Government Printing Office; April, 1995.
  • 115
    American College of Physicians. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med. 1997;126(3):80810.
  • 116
    Institute for Clinical Systems Improvement (ICSI) Health Care Guideline: Colorectal cancer screening. Available at: http://www icsi org/guide/Colon pdf 1999.
  • 117
    American Gastroenterology Association issues guidelines for colorectal cancer screening. Am Fam Physician. 1997;55(3):28602.
  • 118
    Screening for colorectal cancer–United States, 1992–1993, and new guidelines. MMWR Morb Mortal Wkly Rep. 1996;45(3):10710.
  • 119
    Barry MJ, Mulley AG, Richter JM. Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer. Gastroenterology. 1987;93(3):30110.
  • 120
    Brown K, Burrows C. A prospective cost-effectiveness study of alternative work-up strategies in colorectal cancer screening. Aust Health Rev. 1992;15(3):17689.
  • 121
    Brown ML, Kessler LG. The use of gene tests to detect hereditary predisposition to cancer: economic considerations. J Natl Cancer Inst. 1995;87(3):11316.
  • 122
    Daniels K, McKee M. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation. [published erratum appears in J R Army Med Corps 1996 Feb;142(1) 49]. J R Army Med Corps. 1995;141(3):14250.
  • 123
    Eddy DM. Screening for colorectal cancer. Ann Intern Med. 1990;113(3):37384.
  • 124
    Eddy DM, Nugent FW, Eddy JF, et al. Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology. 1987;92(3):68292.
  • 125
    Fric P, Zavoral M, Dvorakova H, Zoubek V, Roth Z. An adapted program of colorectal cancer screening—7 years experience and cost-benefit analysis. Hepatogastroenterology. 1994;41(3):4136.
  • 126
    Gyrd-Hansen D. Is it cost effective to introduce screening programmes for colorectal cancer? Illustrating the principles of optimal resource allocation. Health Policy. 1997;41(3):18999.DOI: 10.1016/s0168-8510(97)00031-6
  • 127
    Joseph AM, Crowson TW, Rich EC. Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening. J Gen Intern Med. 1988;3(3):1328.
  • 128
    Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology. 1995;109(3):178190.
  • 129
    Manus B, Bragelmann R, Armbrecht U, Stolte M, Stockbrugger RW. Screening for gastrointestinal neoplasia: efficacy and cost of two different approaches in a clinical rehabilitation centre. Eur J Cancer Prev. 1996;5(3):4955.
  • 130
    Markowitz AJ, Winawer SJ. Screening and surveillance for colorectal carcinoma. Hematol Oncol Clin North Am. 1997;11(3):579608.
  • 131
    Morey SS. ACS updates guidelines on screening for colorectal cancer. Am Fam Physician. 1997;56(3):18878.
  • 132
    Neilson AR, Whynes DK. Cost-effectiveness of screening for colorectal cancer: a simulation model. IMA J Math Appl Med Biol. 1995;12:35567.
  • 133
    Petrelli NJ, Palmer M, Michalek A, et al. Massive screening for colorectal cancer. A single institution's public commitment. Arch Surg. 1990;125(3):104951.
  • 134
    Salkeld G, Young G, Irwig L, Haas M, Glasziou P. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia. Aust N Z J Public Health. 1996;20(3):13843.
  • 135
    Shimbo T, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care. 1994;10(3):35975.
  • 136
    Tsuji I, Fukao A, Shoji T, Kuwajima I, Sugawara N, Hisamichi S. Cost-effectiveness analysis of screening for colorectal cancer in Japan. Tohoku J Exp Med. 1991;164(3):26978.
  • 137
    Wagner JL. Cost-effectiveness of colorectal cancer screening in the elderly. Ann Intern Med. 1991;115(3):80717.
  • 138
    Walker A, Whynes DK. Filtering strategies in mass population screening for colorectal cancer: an economic evaluation. Med Decis Making. 1992;12(3):27.
  • 139
    Weller D, Moss J, Hiller J, Thomas D, Edwards J. Screening for colorectal cancer: what are the costs? Int J Technol Assess Health Care. 1995;11(3):2639.
  • 140
    Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer: is it cost-effective? Health Econ. 1998;7(3):219.
  • 141
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, Canadian Association of Radiation Oncologists. The palpable breast lump: information and recommendations to assist decision-making when a breast lump is detected. CMAJ. 1998;158:3S8S.
  • 142
    Wright JR, Whelan TJ, McCready DR, O'Malley FP. Management of ductal carcinoma in situ of the breast. Provincial Breast Cancer Disease Site Group. Cancer Prev Control. 1998;2(3):3129.
  • 143
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, Canadian Association of Radiation Oncologists. The management of ductal carcinoma in situ (DCIS). CMAJ. 1998;158:27S34S.
  • 144
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Adjuvant systemic therapy for women with node-positive breast cancer. CMAJ. 1998;158:52S64S.
  • 145
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, Canadian Association of Radiation Oncologists. Axillary dissection. CMAJ. 1998;158:22S6S.
  • 146
    Blichert-Toft M, Smola MG, Cataliotti L, O'Higgins N. Principles and guidelines for surgeons—management of symptomatic breast cancer. On behalf of the European Society of Surgical Oncology. Ann Chir Gynaecol. 1998;87(3):1019.
  • 147
    Cady B, Steele GDJ, Morrow M, et al. Evaluation of common breast problems: guidance for primary care providers. CA Cancer J Clin. 1998;48(3):4963.
  • 148
    Flett MM, Going JJ, Stanton PD, Cooke TG. Sentinel node localization in patients with breast cancer. Br J Surg. 1998;85(3):9913.
  • 149
    Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998;90(3):16018.
  • 150
    Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998;16(3):97985.
  • 151
    Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol. 1998;16(3):10229.
  • 152
    Layfield LJ, Chrischilles EA, Cohen MB, Bottles K. The palpable breast nodule. A cost-effectiveness analysis of alternate diagnostic approaches. Cancer. 1993;72(3):164251.
  • 153
    Lazovich D, Solomon CC, Thomas DB, Moe RE, White E. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 1999;86(3):62837.DOI: 10.1002/(sici)1097-0142(19990815)86:4<628::aid-cncr11>;2-l
  • 154
    Lee CH, Egglin TK, Philpotts L, Mainiero MB, Tocino I. Cost-effectiveness of stereotactic core needle biopsy: analysis by means of mammographic findings. Radiology. 1997;202(3):84954.
  • 155
    Liberman L, Fahs MC, Dershaw DD, et al. Impact of stereotaxic core breast biopsy on cost of diagnosis. Radiology. 1995;195(3):6337.
  • 156
    Liberman L, Feng TL, Dershaw DD, Morris EA, Abramson AF. US-guided core breast biopsy: use and cost-effectiveness. Radiology. 1998;208(3):71723.
  • 157
    Liljegren G, Karlsson G, Bergh J, Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol. 1997;8(3):75763.
  • 158
    Lindfors KK, Rosenquist CJ. Needle core biopsy guided with mammography: a study of cost-effectiveness. Radiology. 1994;190(3):21722.
  • 159
    Lockett MA, Metcalf JS, Baron PL, et al. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic disease in axillary lymph nodes of breast cancer patients. Am Surg. 1998;64(3):53943.
  • 160
    Logan-Young W, Dawson AE, Wilbur DC, et al. The cost-effectiveness of fine-needle aspiration cytology and 14-gauge core needle biopsy compared with open surgical biopsy in the diagnosis of breast carcinoma. Cancer. 1998;82(3):186773.DOI: 10.1002/(sici)1097-0142(19980515)82:10<1867::aid-cncr8>;2-r
  • 161
    Mirsky D, O'Brien SE, McCready DR, Newman TE, Whelan TJ, Levine MN. Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group. Cancer Prev Control. 1997;1(3):107[published erratum appears in Cancer Prev Control 1997 Jun;1(2) 132].
  • 162
    Morrow M, Bland KI, Foster R. Breast cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines. Oncology (Huntingt). 1997;11(3):87781, 8856.
  • 163
    Norum J, Olsen JA, Wist EA. Lumpectomy or mastectomy? Is breast conserving surgery too expensive? Breast Cancer Res Treat. 1997;45(3):714.
  • 164
    O'Higgins N, Linos DA, Blichert-Toft M, et al. European guidelines for quality assurance in the surgical management of mammographically detected lesions. Eur J Surg Oncol. 1998;24(3):968.
  • 165
    Vetto J, Schmidt W, Pommier R, et al. Accurate and cost-effective evaluation of breast masses in males. Am J Surg. 1998;175(3):3837.
  • 166
    Warmerdam PG, De Koning HJ, Boer R, et al. Quantitative estimates of the impact of sensitivity and specificity in mammographic screening in Germany. J Epidemiol Community Health. 1997;51(3):1806.
  • 167
    Gerard K, Seymour J, Smoker I. A tool to improve quality of reporting published economic analyses. Int J Technol Assess Health Care. 2000;16(3):10010.